Work in progress. This site is being built in the open. No page on it has yet been reviewed by a clinician, every page says so, and nothing here is medical advice or a substitute for seeing someone about your knee. What that means
KneeSchool

KneeSchool/Imaging Academy/Tumour Protocol

Tumour Protocol

Page 5.5.5 · MRI of the Knee · imaging page

The protocol for a suspected mass, which is the one knee study whose job is to decide what happens next rather than to make a diagnosis.

Pipeline status. Editorial draft. Evidence verification did not run. Not consultant reviewed. Not for clinical use.

The same topic at 4 depths

Each tier deepens the one below it and never repeats it. Choose the level you want.

Tumour Protocol

Choose a depth

For Medical Students

What It Shows

A tumour protocol images a suspected bone or soft tissue mass, its extent and its relationship to the structures around it. 5.13.7 covers bone tumours.

It covers the whole lesion and the whole compartment rather than only the joint, which the routine knee protocol does not. 5.5.1 covers the standard protocol.

It matters because the study's purpose is staging and referral rather than diagnosis, and a knee protocol run on a mass answers the wrong question. 5.1.3 covers choosing the correct investigation.

How It Is Acquired

Extend the field of view to include the whole lesion and the whole bone where a bone lesion is suspected. 5.13.7 covers bone tumours.

Acquire T1 weighted sequences, which show marrow replacement and the lesion's extent best. 5.2.13 covers T1 imaging.

Acquire fluid sensitive sequences for oedema and for the soft tissue component. 5.2.16 covers fat suppression.

Give intravenous contrast where the question needs enhancement, which is one of the few knee indications for it. 5.2.21 covers advanced magnetic resonance techniques.

Do not biopsy or plan on this study alone, because a suspected tumour belongs to a specialist service. 5.13.7 covers bone tumours.

What Normal Looks Like

Normal fatty marrow throughout the imaged bone on the T1 sequences. 5.2.13 covers T1 imaging.

Normal muscle compartments without a mass or oedema. 5.5.13 covers the neurovascular structures.

No abnormal enhancement where contrast was given. 5.2.21 covers advanced magnetic resonance techniques.

Intact cortical outlines. 5.5.6 covers the bones.

What Abnormal Looks Like

Marrow replacement, darker than fat on the T1 sequences. 5.2.13 covers T1 imaging.

A soft tissue mass with its own signal characteristics and enhancement. 5.2.21 covers advanced magnetic resonance techniques.

Cortical destruction or periosteal reaction. 5.5.6 covers the bones.

Involvement of the neurovascular bundle, which changes the surgical options. 5.5.13 covers the neurovascular structures.

Key Learning Points

  • The protocol images the whole lesion and the whole compartment.
  • The purpose is staging and referral rather than diagnosis.
  • T1 weighted sequences show marrow replacement and extent best.
  • Intravenous contrast is one of the few knee indications.
  • A suspected tumour belongs to a specialist service.

MRCS Level

How It Is Acquired

In a viva the expected answer says what the study is for before describing it.

The expected points are the extended field of view, the T1 sequences, the fluid sensitive sequences, the contrast, and the referral.

Say that the study stages rather than diagnoses. 5.13.7 covers bone tumours.

Say that a knee protocol on a suspected mass is the wrong study. 5.5.1 covers the standard protocol.

Say that biopsy planning belongs to the specialist service. 5.13.7 covers bone tumours.

What Abnormal Looks Like

The reasoning expected is that normal marrow is fat and bright on T1, so anything replacing it is dark, which makes T1 the sequence that defines a lesion's extent. 5.2.13 covers T1 imaging.

Extent is what the specialist service needs, because it determines resectability and the biopsy route, and a study cropped to the joint cannot supply it. 5.5.6 covers the bones.

A biopsy through the wrong route contaminates compartments and changes the operation, which is why the imaging precedes the biopsy and the specialist plans both. 5.13.7 covers bone tumours.

Neurovascular involvement is the finding that most changes the options, which is why the protocol covers the bundle. 5.5.13 covers the neurovascular structures.

How Good It Is

The tumour protocol stages a lesion well and rarely gives a histological diagnosis.

Its best contribution is extent, compartment involvement and the relationship to the neurovascular bundle. 5.5.13 covers the neurovascular structures.

It is limited for the diagnosis itself, which needs histology, and a confident imaging diagnosis of a malignant lesion is the error to avoid. 5.13.7 covers bone tumours.

No figures appear for accuracy on this page, under decision 028, and no size or staging thresholds appear either: those are published quantities and this environment cannot check them.

Key Learning Points

  • Normal marrow is fat, so anything replacing it is dark on T1.
  • Extent determines resectability and the biopsy route.
  • A study cropped to the joint cannot supply extent.
  • A biopsy through the wrong route changes the operation.
  • Neurovascular involvement most changes the options.

FRCS Level

How Good It Is

At decision level this study's purpose is to get the patient to the right place with the right information.

A suspected primary bone or soft tissue malignancy is a referral, and the imaging supports it rather than preceding a local procedure. 5.13.7 covers bone tumours.

Extent and compartment involvement are what the specialist service needs before planning a biopsy. 5.5.6 covers the bones.

A lesion that is confidently benign on imaging may still need review, and the threshold for that is deliberately low. 5.14.6 covers synovial chondromatosis.

A knee study that incidentally shows a marrow lesion should trigger this protocol rather than a conclusion. 5.13.1 covers bone marrow oedema.

Where It Misleads

The commonest error is reporting a mass from a knee protocol that did not cover it. 5.5.1 covers the standard protocol.

A biopsy is taken before the staging imaging. 5.13.7 covers bone tumours.

A confident imaging diagnosis is made where histology was needed. 5.13.7 covers bone tumours.

Normal red marrow is read as replacement. 5.2.13 covers T1 imaging.

Contrast is given where it changes nothing. 5.2.21 covers advanced magnetic resonance techniques.

Key Learning Points

  • A mass is reported from a protocol that did not cover it.
  • A biopsy is taken before the staging imaging.
  • A confident imaging diagnosis replaces histology.
  • Normal red marrow is read as replacement.
  • Contrast is given where it changes nothing.

Fellowship Level

Where It Misleads

At fellowship level this protocol sits at a boundary where an imaging decision has consequences outside imaging.

The study's job is to route the patient, so a study that is adequate for the knee and inadequate for the lesion is worse than no study, because it supports a local decision that should not have been made. 5.13.7 covers bone tumours.

A biopsy route chosen without staging imaging can contaminate a compartment and convert a limb sparing operation into a larger one, which makes the imaging sequence a surgical matter. 5.5.6 covers the bones.

Most marrow abnormality found incidentally on a knee study is not tumour, so the threshold has to balance over-investigation against the one case where it matters. 5.13.1 covers bone marrow oedema.

Advanced techniques have been proposed to characterise lesions and none replaces histology, so the imaging's role stays at extent rather than identity. 5.2.21 covers advanced magnetic resonance techniques.

The settled practice is that a suspected malignant lesion goes to a specialist service before anything else happens, and the imaging's contribution is to make that referral well informed. 5.1.4 covers imaging pathways.

Key Learning Points

  • A study adequate for the knee and inadequate for the lesion is worse than none.
  • A biopsy route chosen without staging can enlarge the operation.
  • Most incidental marrow abnormality is not tumour.
  • Advanced characterisation does not replace histology.
  • The imaging's job is a well informed referral.

Explore Further

Where this topic came from and where it goes next in the spiral.

References

No reference list is attached to this draft. Evidence verification has not run, because source retrieval was unavailable at generation time. Under the Operations Handbook a missing reference is acceptable and an invented one is a critical failure, so nothing has been cited and no citation marker appears in the text. This page carries no diagnostic accuracy figure, which is decision 028 rather than an omission: the comparative standing of the modalities is standard teaching and a specific sensitivity written from memory is the same class of claim as an invented citation, so ACC-001 refuses the number and the page states the comparison. A reviewer with the literature can add the figures into How Good It Is without restructuring the page. Any measurement here, including a sequence parameter, an angle or a millimetre, is written from standard teaching, has not been checked, and is registered under decision 006 in pipeline/config/figures with a verification state of UNVERIFIED_FROM_MEMORY.

Safety. KneeSchool is educational and does not give individual medical advice. Seek urgent assessment for a knee that cannot bear weight after an injury, a hot swollen knee with a fever, or new numbness, weakness or coldness in the leg or foot.